CD274 and non-small cell lung carcinoma: Though PD-L1 expression and tissue-based tumor mutational burden (tTMB) have been proven to be useful predictive biomarkers for patients with advanced NSCLC treated with ICIs [4,5], sufficient high-quality tissue samples for standard biomarker analysis were available only for a minority of patients [6].